von Scheele B, David K, Gaffney L, Niculescu L, Verburg KM. The total cost of treatment and the cost-effectiveness of valdecoxib vs diclofenac in the treatment of patients with osteoarthritis (OA) of the hip and/or knee. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6):661.
Alten RH, von Scheele B, Gaffney L, Maciver F, Niculescu L. Cost-effectiveness of valdecoxib compared to diclofenac in patients with rheumatoid arthiritis (RA) in the United Kingdom (UK) and Germany. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6).
Johannes CB, Schneider GA, Walker AM, Viveash D, Wallis WJ. Increased incidence of lymphoma among patients with rheumatic diseases based on automated insurance claims information. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13:S239.
Johannes CB, Schneider GA, Walker AM, Zhao S, Shibata A. Validation of a propensity score developed using claims data in controlling for health status of rheumatic disease patients initiating etanercept compared with other DMARDS. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(S1):S16.
Johannes CB, Zhao S, Shibata A, Schneider G, Wallis W, Walker A. Propensity score analysis in balancing underlying disease severity among rheumatic disease patients treated with etanercept or another DMARD. Poster presented at the American College of Rheumatology Annual Scientific Meeting; 2004.